How many drugs treat Acute otitis media?

Drug Landscape tracks 10 marketed treatments for Acute otitis media (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acute-otitis-media.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acute otitis media — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute otitis media (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute otitis media, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cefpodoxime Proxetil	CEFPODOXIME	Pfizer			2007-01-01
Cedax	ceftibuten	Burke Therap	Cephalosporin Antibacterial		1995-01-01
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Cefradex	cefradine	Bristol-Myers Squibb	cefradine	Matrix metalloproteinase-9	1974-01-01
Trimethoprim	TRIMETHOPRIM	Dr Reddys Labs Sa	Sulfonamide Antimicrobial [EPC]	Dihydrofolate reductase	1973-01-01
Azo Gantanol	SULFAMETHOXAZOLE	Pfizer	Sulfonamide Antimicrobial [EPC]		1973-01-01
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 4 drugs in Acute otitis media
· 3 drugs in Acute otitis media
Bristol-Myers Squibb · 2 drugs in Acute otitis media
GSK · 2 drugs in Acute otitis media
Generic (originally Abbott/AbbVie) · 1 drug in Acute otitis media
Generic (originally Abbott/Lilly) · 1 drug in Acute otitis media
Generic (originally Beecham/GSK) · 1 drug in Acute otitis media
Karlstad University · 1 drug in Acute otitis media
Katarina Hedin · 1 drug in Acute otitis media
King George's Medical University · 1 drug in Acute otitis media
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · 1 drug in Acute otitis media
Shionogi · 1 drug in Acute otitis media

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute otitis media:

Cite this brief

Drug Landscape (2026). Acute otitis media — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-otitis-media. Accessed 2026-06-10.

Acute otitis media full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing